Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

E4512- A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Purpose of this study is to compare any good and bad effects of using the study drug, crizotinib after completeion of surgery and in some cases after chemotherapy and/or radiation therapy for ALK-positive non-small cell lung cancer.

Marc Rovito
Michelle Eschbach - at or 610-378-2336

18 year(s) or older
This study is NOT accepting healthy volunteers
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Patients must have undergone complete surgical resection of their
Patients must be registered to the ALCHEMIST-SCREEN (ALLIANCE
ALK positive
Patients must have completed any prior adjuvant chemotherapy or

Exclusion Criteria:
No prior treatment with crizotinib or another ALK inhibitor.
I'm interested
Share via email
See this study on
Show 1 location

Study Locations

Hide all locations
Location Contacts
Reading, PA ,